Employing siRNA library screening, scientists identified that silencing the m6A writer methyltransferase-like 3 (METTL3) significantly enhanced the sensitivity to oxaliplatin in both in vivo and in vitro hepatocellular carcinoma models.
[Cell Death & Differentiation]